Has Krishna Dass, MD received payments from drug or device companies?

Yes. Drug and device makers reported $38 in general payments to Krishna Dass, MD across 2 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Krishna Dass, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Krishna Dass, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Krishna Dass, MD

Infectious Disease · Washington, DCNPI 1598739724

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. That places this record below the midpoint for infectious disease clinicians in DC, where the typical reported total is $240.

$38in general payments, 2019–2025

Across 2 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$20
Smith+Nephew$18

What the payments were for

Food & beverage$38100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	1	$20
Smith+Nephew	1	$18

How this compares

$38 in reported general payments places this provider in the 20th percentile of 74 infectious disease providers in District of Columbia.

See all infectious disease providers in District of Columbia →

Medicare billing

Part B allowed, 2024

$375,345

Medicare patients

738

Services billed

3,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	60	$245,572
JulucaDolutegravir/Rilpivirine	42	$173,341
GenvoyaElviteg/Cob/Emtri/Tenof Alafen	13	$70,292
TivicayDolutegravir Sodium	14	$29,997
EdurantRilpivirine Hcl	11	$15,313
Cefazolin Sodium	13	$695

Paid to pharmacies, not to this prescriber.

Other infectious disease in Washington

Jesse GoodmanWashington$1.8M
Theo HodgeWashington$1M
Robert GasserWashington$922K
Princy KumarWashington$270K
Jose ChavezWashington$254K
Linda NabhaWashington$60K
Gebeyehu TeferiWashington$25K
Jose BordonWashington$12K
Rebecca KumarWashington$12K
Jeffrey MurrayWashington$8K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →